The Committee recommends that phase III trials should be conducted that compare alitretinoin with ciclosporin, azathioprine and PUVA in people who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids.
The Committee recommends that a study should be conducted that estimates utility values using directly observed health-related quality of life values (such as EQ-5D scores) in people with severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids.